Illexcor Therapeutics focuses on discovering and developing new oral treatments for sickle cell disease.
Illexcor Therapeutics has raised $13.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2026.
Illexcor Therapeutics's investors include Zynext Ventures.
Illexcor Therapeutics is headquartered in Richmond, United States.
Illexcor Therapeutics focuses on discovering and developing new oral treatments for sickle cell disease.
Illexcor Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Illexcor Therapeutics — Funding & Investors." VCBacked, May 7, 2026, https://www.vcbacked.co/company/illexcor-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Illexcor Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/illexcor-therapeutics
{{cite web |title=Illexcor Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/illexcor-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated